Abstract
Brain metastases (BM) are one of the most frequent neurological complications of cancers. Melanoma is the third most common tumor to metastasize to the brain with a reported incidence of 10–40 %, and many patients have subclinical BM (>73 %). We computer-searched the clinical records of all our patients registered into a database to identify patients that presented or developed BM. A total of 49 patients with melanoma BM were included in our analysis. General time to brain metastases (TTBM) was 23 months. The nonparametric test between TTBM and the single variables showed an association between TTBM and Breslow thickness (p < 0.0076; Spearman’s coefficient—0.411), ulceration (p = 0.0656; Spearman’s coefficient—0.287) and positive sentinel lymph node (p < 0.0015; Spearman’s coefficient—0.475). Performing multiple regression, positive SLN remained the only, statistically significant, predictive variable (p < 0.01). Regarding the first melanoma site, the axial sites were more likely to develop BM than peripheral ones (p < 0.001). The analysis of brain metastasis survival (BMS) with Kaplan–Meier curves has resulted in a median survival rate of 6 months (range 1–134 months) and was strongly related to response to treatment, number of parenchymal lesions, presence or absence of symptoms. The results of the current analysis revealed clinical and primary tumor characteristics associated with the development of BM, TTBM, and BMS. The SNL was found to be the strongest predictor for BM development.
Similar content being viewed by others
References
Nayak L, Quant Lee E, Wen PY. Epidemiology of brain metastases. Cur Oncol Rep. 2012;14:48–54.
De Angelis LM, Posner JB. Neurologic complications of cancer. New York: Oxford University Press; 2009.
Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973–2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol. 2004;22:2865–72.
Fabi A, Felici A, Metro G, Mirri A, Bria E, Telera S, et al. Brain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating center. J Exp Clin Cancer Res. 2011;30:10.
Counsell CE, Collie DA, Grant R. Incidence of intracranial tumors in the Lothian region of Scotland, 1989–1990. J Neurol Neurosurg Psychiatry. 1996;61:143–50.
Flanigan JC, Jilaveanu LB, Faries M, Sznol M, Ariyan S, Yu JB, et al. Melanoma brain metastases: is it time to reassess the bias? Curr Probl Cancer. 2011;35:200–10.
Patel JK, Didolkar MS, Pickren JW, Moore RH. Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. Am J Surg. 1978;135:807–10.
de la Monte SM, Moore GW, Hutchins GM. Patterned distribution of metastases from malignant melanoma in humans. Cancer Res. 1983;43:3427–33.
Sampson JH, Carter JH Jr, Friedman AH, Seigler HF. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg. 1998;88:11–20.
Zakrzewski J, Geraghty LN, Rose AE, Christos PJ, Mazumdar M, Polsky D, et al. Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival. Cancer. 2011;117:1711–20.
Trinh VA, Hwu W-J. Chemoprevention for brain metastases. Curr Oncol Rep. 2012;14:63–9.
Meier S, Baumer BG, Maier T, Wellis G, Burg G, Seifert B, et al. Survival and prognostic factors in patients with brain metastases from malignant melanoma. Onkologie. 2004;27:145–9.
Raizer JJ, Hwu WJ, Panageas KS, Wilton A, Baldwin DE, Bailey E, et al. Brain and leptomeigeal metastases from cutaneous melanoma: survival outcomes based on clinical features. Neuros Oncol. 2008;10:199–207.
Balch CM, Soong S, Ross MI, Urist MM, Karakousis CP, Temple WJ, et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0–4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Onco 2000;l7:87–7.
Eigenther TK, Figl A, Krex D, Mohr P, Mauch C, Rass K, et al. Number of metastases, serum lactate deydrogenase level, and type of treatment and prognostic factors in patients with brain metasatses of malignant melanoma. Cancer. 2011;117:1697–703.
Grob JJ, Regis J, Laurans R, Delaunay M, Wolkenstein P, Paul K, et al. Radiosurgery without whole brain radiotherapy in melanoma brain metastases. Club de cancerologie Cutanee. Eur J Cancer. 1998;10:1187–92.
Raizer JJ, Hwu WJ, Pangeas KS, Wilton A, Baldwin DE, Bailey E, et al. Brain and leptomenigeal metastases from cutanous melanoma: survival outcomes based on clinical features. Neuro Oncol. 2008;10:199–207.
Davies MA, Liu P, McIntyre S, Kim KB, Papadopoulos N, Hwu WJ, et al. Prognostic factors for survival in melanoma patients with brain metastases. Cancer. 2011;117:1687–96.
Retsas S, Gershuny AR. Central nervous system involvement in malignant melanoma. Cancer. 1988;61:1926–34.
Staudt M, Lasithiotakis K, Leiter U, Meier F, Eigentler T, Bamberg M, et al. Determinants of survival in patients with brain metastases from cutaneous melanoma. Br J Cancer. 2010;102:1213–8.
Boogerd W, de Gast GC, Dalesio O. Temozolomide in advanced malignant melanoma with small brain metastases: can we withhold cranial irradiation? Cancer. 2007;109:306–12.
Schild SE, Behl D, Markovic SN, Brown PD, Sande JR, Deming RL, et al. Brain metastases from melanoma: is there a role for concurrent temozolomide in addition to whole brain radiation therapy? Am J Clin Oncol. 2010;33:633–6.
Fife KM, Colman MH, Stevens GN, Firth IC, Moon D, Shannon KF, et al. Determinants outcome in melanoma patients with cerebral metastases. J Clin Oncol. 2004;22:1293.
Buchsbaum JC, Suh JH, Lee SY, Chidel MA, Greskovich JF, Barnett GH. Survival by Radiation Therapy Oncology Group recursive partitioning analysis class and treatment modality in patients with brain metastases from malignant melanoma: a retrospective study. Cancer. 2002;94:2265–72.
Harrison BE, Johnson JL, Clough RW, Halperin EC. Selection of patients with melanoma brain metastases for aggressive treatment. Am J Clin Oncol. 2003;26:354–7.
Madajewicz S, Karakousis C, West CR, Caracandas J, Avellanosa AM. Malignant melanoma brain metastases. Review of Roswell Park Memorial Institute experience. Cancer. 1984;53:2550–2.
Le Scodan R, Jouanneau L, Massard C, Gutierrez M, Kirova Y, Cherel P, et al. Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death. Cancer. 2011;11:395.
Zacest AC, Besser M, Stevens G, Thompson JF, McCarthy WH, Culjak G. Surgical management of cerebral metastases from melanoma: outcome in 147 patients treated at a single institution over two decades. J Neurosurg. 2002;96:552.
Kaye AH, Lawws ER Jr. Brain tumors. An encyclopedic approach. New York: Churchill Livingstone; 1995.
Ewend MG, Carey LA, Brem H. Treatment of melanoma metastases in the brain. Semin Surg Oncol. 1996;12:429.
Wronski M, Arbit E. Surgical treatment of brain metatsases from melanoma: a retrospective study of 91 patients. J Neurosurg. 2000;93:9–18.
Goldlust SA, Hsu M, Lassman AB, Panageas KS, Avila EK. Seizure prophylaxis and melanoma brain metastases. J Neuroncol. 2012;108:109–14.
Goulart RC, Mattei TA, Ramina R. Cerebral melanoma metastases: a critical review on diagnosis methods and therapeutic options. ISNR Surg 276908 (2011).
Bottoni U, Bonaccorsi P, Devirgiliis V, Panasiti V, Borroni RG, Trasimeni G, et al. Complete remission of brain metastases in three patients with stage IV melanoma treated with BOLD and G-CSF. Jpn J Clin Oncol. 2005;35:507–13.
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bottoni, U., Clerico, R., Paolino, G. et al. Predictors and survival in patients with melanoma brain metastases. Med Oncol 30, 466 (2013). https://doi.org/10.1007/s12032-013-0466-2
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s12032-013-0466-2